ABL Bio Balance Sheet Health
Financial Health criteria checks 3/6
ABL Bio has a total shareholder equity of ₩63.8B and total debt of ₩43.0B, which brings its debt-to-equity ratio to 67.4%. Its total assets and total liabilities are ₩140.8B and ₩77.0B respectively.
Key information
67.4%
Debt to equity ratio
₩43.00b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩53.22b |
| Equity | ₩63.81b |
| Total liabilities | ₩76.95b |
| Total assets | ₩140.76b |
Recent financial health updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16
Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Financial Position Analysis
Short Term Liabilities: A298380's short term assets (₩56.5B) exceed its short term liabilities (₩32.7B).
Long Term Liabilities: A298380's short term assets (₩56.5B) exceed its long term liabilities (₩44.2B).
Debt to Equity History and Analysis
Debt Level: A298380 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A298380's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A298380 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A298380 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.